Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit

Revisão Revisado por pares

2015; Adis, Springer Healthcare; Volume: 38; Issue: 8 Linguagem: Inglês

10.1007/s40264-015-0300-1

ISSN

1179-1942

Autores

Rashmi R. Shah, Joel Morganroth,

Tópico(s)

HER2/EGFR in Cancer Research

Ver no editor

Altmetric

PlumX